T-Therapeutics develops T cell receptor-based therapeutics using its proprietary OpTiMus® platform, which generates fully human T cell receptors that target specific cancer antigens. This technology addresses the limitations of current immuno-oncology treatments by enhancing T cell specificity and efficacy, potentially reducing side effects and improving patient outcomes in cancer therapy.
Funding
$58.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CIFounders
Product
Problem
Current immuno-oncology treatments, such as checkpoint inhibitors and T cell engagers, have limitations in specificity and efficacy, leading to potential side effects and limited success across different cancer types. These drugs, while enabling the body’s own T cells to recognize and kill cancer cells, often lack the precision needed to target tumors effectively without harming healthy tissues.
Solution
T-Therapeutics is developing T cell receptor (TCR)-based therapeutics designed to recognize specific cancers and recruit a patient’s own T cells to eradicate tumors. The company's proprietary OpTiMus® platform generates fully human TCRs that do not exist in the human repertoire, providing a unique approach to cancer therapy. By harnessing the natural power of T cells and engineering optimal TCRs, T-Therapeutics aims to create a portfolio of transformational medicines with enhanced specificity and reduced side effects. The OpTiMus® platform is capable of producing a large number of human TCRs with unique properties, making them ideal for developing pioneering cancer therapies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel immuno-oncology therapeutics with improved efficacy and reduced toxicity.
Features
- OpTiMus® platform: A fully humanized TCR mouse platform generating fully human TCRs not found in the human repertoire.
- Identification of ‘optimal’ T cell receptors (TCRs) as building blocks for cancer therapies.
- TCR-based drugs designed to recognize specific cancers.
- Capability to recruit the patient’s own T cells to kill cancer cells.
- Expertise in mouse genome engineering, biopharmaceutical drug development, single-cell genomics, machine learning, and structural biology.